SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

January 11, 2011 08:45 ET

Radient Pharmaceuticals Comments on Recent News of J&J's Planned Cancer Test; Announces Growing Worldwide Availability of Its Onko-Sure® Cancer Test

TUSTIN, CA--(Marketwire - January 11, 2011) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, responded today on Johnson & Johnson's recent news announcing the research and development of a cancer blood test. 

RPC's Chairman and CEO Douglas MacLellan commented, "Johnson and Johnson's news is indeed very exciting for the scientific, medical, and public communities at large. Every advance the cancer diagnostic industry makes that brings us closer to conquering this deadly disease is a critical step forward in the quest to save millions of lives. RPC continues to actively communicate the merits and availability of its FDA-cleared Onko-Sure® IVD cancer test -- a simple, non-invasive blood test proven to monitor and/or detect cancer as early as Duke's Stages A and B, where there is the highest probability of successful treatment due to early diagnosis."

In comparison to RPC's Onko-Sure® IVD cancer test, J&J's unnamed test:

  • Is in the preliminary stage of research, development and experimentation;
  • Is being tested to identify precisely what materials can be used on the slides/chips in order to increase the efficiency and decrease the price of the test;
  • Has not been through clinical trials and has clinical data backing; and,
  • Is not FDA-approved. (FDA approvals typically take no less than 4-5 years to secure.)

RPC's Onko-Sure® cancer test is a regulatory‐approved and sensitive IVD test that enables physicians and their patients to effectively detect and/or monitor over 19 types of cancer. Test highlights include:

  • A collaborative clinical study is ongoing with the Mayo Clinic to compare the efficiency of Onko-Sure with CEA in the detection of colorectal cancer. The final test results are expected to be announced in Q1 2011.
  • Onko-Sure® has been positively reviewed in more than 50 scientific publications.
  • RPC has been invited to present at various scientific and medical conferences, including the upcoming European Multidisciplinary Conference in Thoracic Oncology (EMCTO) international conference, 24-26 February 2011, where the Company will present an abstract under the title of "The Validation of Fibrin and Fibrinogen Degradation Products Assay for Early Detection of Lung Cancer."
  • Onko-Sure® is a clinically-proven cancer marker. Greater than 50% of all colorectal cancer patients with biopsy-confirmed CRC have low CEA values and cannot be detected by CEA test, however, Onko-Sure is very sensitive in the lower level of the marker (DR-70) and can detect them. Therefore, combination of Onko-Sure® and CEA should add significantly to the clinical value for monitoring CRC patients.
  • Onko-Sure® has international regulatory approvals as a cancer detection and monitoring tool in more than seven countries.
  • For Clinical Testing and Services please go to: http://amdl.com/onkosure/clia-usa.html or to speak with a representative please call (877) 496-8837 or e-mail cliaservices@genwaybio.com.

RPC's Onko-Sure® cancer test is a regulatory‐approved and sensitive IVD test that enables physicians and their patients to effectively detect and/or monitor over 19 types of cancer, including lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic and others, by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. RPC's Onko-Sure® cancer test has been proven effective in assessing whether a patient's cancer is progressing during treatment or if their cancer has returned or remains in remission. In clinical trials, the test kit has demonstrated the ability to detect the presence of certain cancers in humans 84 percent of the time overall. RPC's Onko-Sure® test is a valuable diagnostic tool in the worldwide battle against cancer -- the second leading cause of death worldwide.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or send e-mail to info@radient-pharma.com. For Investor Relations contact Kristine Szarkowitz at IR@RadientPharma.com or 1.206.310.5323.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • RPC Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel : ) 206.310.5323